Data gathered: September 18
Alternative Data for Sagimet Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | 61 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 15 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,882 | Sign up | Sign up | Sign up |
| Twitter Followers | 257 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 20 | Sign up | Sign up | Sign up |
About Sagimet Biosciences
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways.
| Price | $6.15 |
| Target Price | Sign up |
| Volume | 567,410 |
| Market Cap | $202M |
| Year Range | $1.9 - $10.24 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Sagimet Biosciences reports data from Phase 3 trial on denifanstatSeptember 17 - Thefly.com |
 |
Wall Street Zen Downgrades Sagimet Biosciences (NASDAQ:SGMT) to SellSeptember 12 - ETF Daily News |
|
Trexquant Investment LP Invests $85,000 in Sagimet Biosciences Inc. $SGMTSeptember 11 - ETF Daily News |
|
Sagimet Biosciences announces presentations at MASH Drug Development SummitSeptember 10 - Thefly.com |
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development SummitSeptember 10 - GlobeNewswire |
|
|
American Century Companies Inc. Grows Holdings in Sagimet Biosciences Inc. $SGMTSeptember 8 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 0 | 0 | -10M | -12M | -0.320 |
| Q1 '25 | 0 | 0 | 0 | -18M | -20M | -0.560 |
| Q4 '24 | 0 | 0 | 0 | -16M | -16M | -0.500 |
| Q3 '24 | 0 | 0 | 0 | -15M | -17M | -0.450 |
| Q2 '24 | 0 | 0 | 0 | -8.1M | -11M | -0.250 |
Insider Transactions View All
| Martins Eduardo Bruno filed to sell 106,936 shares at $9.1. July 23 '25 |
| Rozek Elizabeth filed to sell 183,726 shares at $9.1. July 23 '25 |
| Happel David filed to sell 689,722 shares at $9.1. July 23 '25 |
| Kemble George filed to sell 118,693 shares at $3.2. July 25 '24 |
| Martins Eduardo Bruno filed to sell 81,213 shares at $3.1. July 23 '24 |
Similar companies
Read more about Sagimet Biosciences (SGMT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Sagimet Biosciences?
The Market Cap of Sagimet Biosciences is $202M.
What is the current stock price of Sagimet Biosciences?
Currently, the price of one share of Sagimet Biosciences stock is $6.15.
How can I analyze the SGMT stock price chart for investment decisions?
The SGMT stock price chart above provides a comprehensive visual representation of Sagimet Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sagimet Biosciences shares. Our platform offers an up-to-date SGMT stock price chart, along with technical data analysis and alternative data insights.
Does SGMT offer dividends to its shareholders?
As of our latest update, Sagimet Biosciences (SGMT) does not offer dividends to its shareholders. Investors interested in Sagimet Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Sagimet Biosciences?
Some of the similar stocks of Sagimet Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.